RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data

Biomarkers in Medicine

Volumn 11, Issue 9, 2017, Pages 751-760

  Kafatos, George ^a   Niepel, Daniela ^b   Lowe, Kimberley ^b   Jenkins Anderson, Sophie ^c   Westhead, Hal ^c   Garawin, Tamer ^b   Traugottová, Zuzana ^d   Bilalis, Antonios ^e   Molnar, Edit ^f   Timar, Jozsef ^g   Toth, Erika ^h   Gouvas, Nikolaos ⁱ   Papaxoinis, George ^j   Murray, Samuel ^k   Mokhtar, Nadia ^l   Vosmikova, Hana ^m   Fabian, Pavel ⁿ   Skalova, Alena ^o   Wójcik, Piotr ^p   Tysarowski, Andrzej ^q   Barugel, Mario ^r   Van Krieken, J Han ^s   Trojan, Jörg ^t   more..

^a AMGEN LTD   (United Kingdom)

^b AMGEN INC   (United States)

^c Adelphi Research (Global)   (United Kingdom)

^d PC Progress Sro   (Czech Republic)

^e Amgen Hellas EPE   (Greece)

^f Amgen Kft   (Hungary)

^g SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^h NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁱ Gastrointestinal Cancer Study Group   (Greece)

^j UNIVERSITY OF ATHENS   (Greece)

^k BioMarker Solutions   (United Kingdom)

^l CAIRO UNIVERSITY   (Egypt)

^m UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

ⁿ MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^o BIOPTICAL LABORATORY   (Czech Republic)

^p Oncogene Diagnostics Sp z oo   (Poland)

^q INSTITUTE OF ONCOLOGY   (Poland)

^r Tecnofarma   (Chile)

^s RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^t UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

anti EGFR; BRAF; KRAS; mCRC; metastatic colorectal cancer; NRAS; prevalence; RAS; real world

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; OBSERVATIONAL STUDY; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PREVALENCE; COLORECTAL TUMOR; EXON; GENETICS; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; SURVIVAL RATE;

B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; EXONS; HUMANS; MUTATION; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE;

EID: 85029806830     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm-2016-0358     Document Type: Article

References (20)

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol. Biomarkers Prev. 25, 16-27 (2016).
2. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015).
3. van Cutsem E, Cervantes A, Nordlinger B, Arnold D. ESMO Guidelines Working Group. Collaborators (20), Ann. Oncol. 25(Suppl. 3), iii1-iii9 (2014).
4. Tay RY,Wong R, Hawkes EA. Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Manag. Res. 7, 189-198 (2015).
5. Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap. Adv. Gastroenterol. 6, 381-395 (2013).
6. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
7. Schwartzberg LS, Rivera F, Karthaus M et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 32, 2240-2247 (2014).
8. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065-1075 (2014).
9. Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 14, 749-759 (2013).
10. Peeters M, Douillard JY, van Cutsem E et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol. 31, 759-765 (2013).
11. Peeters M, Kafatos G, Taylor A et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials. Eur. J. Cancer 51, 1704-1713 (2015).
12. Boleij A, Tack V, Taylor A et al. RAS testing practices and RAS mutation prevalence amongst mCRC patients: results from a Europe-wide survey of pathology centres. BMC Cancer 16, 825 (2016) (In Press).
13. Peeters M, Oliner KS, Parker A et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin. Cancer Res. 19, 1902-1912 (2013).
14. Sorich MJ, Wiese MD, Rowland A et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann. Oncol. 26, 13-21 (2015).
15. Boleij A, Tops BB, Rombout PD et al. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget 6, 15681-15689 (2015).
16. Wong NA, Gonzalez D, Salto-Tellez M et al. RAS testing of colorectal carcinoma - a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J. Clin. Pathol. 67, 751-757 (2014).
17. Malapelle U, Carlomagno C, de Luca C et al. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. J. Clin. Pathol. 67, 1-9 (2014).
18. van Krieken JH, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 453, 417-431 (2008).
19. Tack V, Ligtenberg MJ, Tembuyser L et al. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. Oncologist 20, 257-262 (2015).
20. Li Y, Fu XH, Yuan JQ et al. Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations. Expert Rev. Anticancer Ther. 15, 715-725 (2015).